Abstract 136P
Background
Even though Serbia is one of the countries with the highest incidence of lung cancer in the world, there is no recent data published on the incidence, mortality, survival time or the most significant patient characteristics for the Northern Serbian Province of Vojvodina.
Methods
For the purpose of this retrospective study we collected data of 21915 patients from seven Public Health Institutes, one for each district. Data of 8142 patients for survival analysis were collected from the Institute for Pulmonary Diseases of Vojvodina Hospital Information System and the Lung Cancer Registry. The primary objective of the study was to determine the impact of demographic and clinical pathological characteristics of patients on overall survival. The secondary objective was to analyze the incidence and mortality of lung cancer in the region of Vojvodina.
Results
A total of 7540 patients were eligible for the survival analysis, 5456 (72.4%) males and 2084 (27.6%) females. The average survival time, including all stages and cancer types was 17.1 months for men and 23.2 months for women (p= 0.000). There was statistically significant difference in survival time by gender in subtypes of adenocarcinoma (p= 0.000), squamous cell carcinoma (p= 0.000) and microcellular carcinoma (p= 0.001). Analysis showed significant difference in survival by age (p= 0.000), cancer type (p= 0.000), stage of the disease (p= 0.000), ECOG performance status (p= 0.000), smoking status (p= 0.001), TNM stage of disease (p= 0.000) and among districts (p= 0.014).
Conclusions
Northern Serbian Province of Vojvodina is one of the regions with the highest incidence and mortality of lung cancer and overall survival is low. Determining the impact of the most important demographic and tumor characteristics on lung cancer patients’ survival, as well as incidence and mortality rates define the parameters necessary for adequate planning of activities and strategies for improving the prevention, diagnosis and treatment of patients in Vojvodina.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.